News
Category: Huntingtons Disease
US Client Clinical Trial Contract Win
10 December 2024 - London, UK. IXICO plc (AIM: IXI, “IXICO” or “the Company”) a global leader in neuroscience imaging, using its AI-driven platform to help advance therapy research in neurological disorders, today announces that it has signed a contract with a new US headquartered client to provide imaging services for a Phase 2 Huntington’s Disease clinical trial.